FREQUENTLY ASKED QUESTIONS
-
While the European and United States markets generate significant revenue for biopharmaceutical companies, they are not the only source of income in the industry. Emerging giants such as Brazil and China together with other global economies make up a significant portion of sales but go largely underreported in financial news sites.
-
A regulatory nod coming ahead of Europe’s EMA and the United States FDA can help gauge the likelihood and timing of the widely advertised EMA and FDA authorizations that commonly drive up developers’ stocks.
-
Generic and biosimilar competitors can enter smaller markets first, which constitutes a red light heralding their imminent arrival to Europe or the United States together with media reports that can erode the stock value of originator companies.
-
Unlike speculative market insights, these are factual data that PHARMALERT mines exclusively for you according to your interests.
-
While EMA approvals (and the subsequent marketing authorisations issued by the European Commission) are valid across the European Union, Iceland, Norway and Liechtenstein, individual countries in the region can authorize medicines that have not completed the centralised review process with the EMA, thus opening additional or early profit opportunities to drug developers. Specialised media usually neglect national-level registrations to focus on EMA decisions.
In addition, bioequivalent medicines are assessed and authorised at local level in the region, meaning that arrivals of first-mover generics or biosimilars stay below the radar of news outlets.
Use our contact form to send us the names of your molecules of interest and we will add them to the list on our website.
Contact us and we will put together a package tailored to your needs, whether you are focusing on a company’s key pipeline programs, products nearing launch, commercial stage therapies or blockbuster molecules.
Certainly. Please use our contact form to request a quotation.